{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276209","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.896860+00:00","generated_at":"2026-05-16T21:12:56.291776+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara Q3 net loss $4.3M; cash $13.7M; tab-cel BLA PDUFA Jan 10, 2026","bullets":["Cash and equivalents $13.7M as of Sep 30, 2025, down from $22.3M at Jun 30.","Net loss of $4.3M ($0.32 per share) vs. $21.9M loss a year ago.","Total revenues $3.5M, down from $40.2M in Q3 2024 due to deferred revenue recognition.","Workforce reduced ~29% in Oct 2025; ~15 employees now retained.","FDA accepted tab-cel BLA with Priority Review; $40M milestone due from Pierre Fabre upon approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276209","json":"https://secwatch.observer/filing/0001193125-25-276209.json","markdown":"https://secwatch.observer/filing/0001193125-25-276209.md","text":"https://secwatch.observer/filing/0001193125-25-276209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/0001193125-25-276209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:12:56.291776+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}